Last reviewed · How we verify

propofol targel controlled infusion

Universidad del Desarrollo · FDA-approved active Small molecule

Propofol is a short-acting intravenous anesthetic that enhances inhibitory GABA neurotransmission in the central nervous system to produce sedation and anesthesia.

Propofol is a short-acting intravenous anesthetic that enhances inhibitory GABA neurotransmission in the central nervous system to produce sedation and anesthesia. Used for Induction and maintenance of general anesthesia, Sedation in intensive care units, Sedation for diagnostic and therapeutic procedures.

At a glance

Generic namepropofol targel controlled infusion
Also known aspropofol TCI
SponsorUniversidad del Desarrollo
Drug classGABA-A receptor positive allosteric modulator
TargetGABA-A receptor
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Propofol acts as a positive allosteric modulator of GABA-A receptors, increasing chloride ion influx and neuronal hyperpolarization. This results in rapid onset of unconsciousness and sedation. Target-controlled infusion (TCI) is a delivery method that uses pharmacokinetic modeling to maintain a constant plasma or effect-site concentration of propofol, allowing for more precise anesthetic control.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: